Leerink Partners Reiterates Outperform Rating on AnaptysBio (ANAB)
Tweet Send to a Friend
Leerink Partners analyst David Risinger reiterated an Outperform rating and $35.00 price target on AnaptysBio (NASDAQ: ANAB)The analyst comments "We ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


